Arixtra Related Published Studies
Well-designed clinical trials related to Arixtra (Fondaparinux Subcutaneous)
FONDAPARINUX FOR ISOLATED SUPERFICIAL-VEIN THROMBOSIS OF THE LEGS: A COST-EFFECTIVENESS ANALYSIS. [2011.07.14]
Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux. [2011.06.06]
Multidetector-row computed tomography-based clinical assessment of fondaparinux for treatment of acute pulmonary embolism and acute deep vein thrombosis in Japanese patients. [2011.05.25]
Comparison of safety and efficacy between fondaparinux and nadroparin in non-ST elevation acute coronary syndromes. [2011.03]
Early postoperative bleeding in polytrauma patients treated with fondaparinux: literature review and institutional experience. [2011.01]
Efficacy and safety of fondaparinux in patients with ST-segment elevation myocardial infarction across the age spectrum. Results from the Organization for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) trial. [2010.12]
Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux. [2010.12]
Fondaparinux for the treatment of superficial-vein thrombosis in the legs. [2010.09.23]
Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial. [2010.02]
Fondaparinux in acute coronary syndromes. [2009.12]
Prospective randomized controlled trial on the effect of fondaparinux sodium for prevention of venous thromboembolism after hip fracture surgery. [2009.09]
Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial. [2009.07.28]
Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial. [2009.05]
Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk. [2009.03]
Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patients. [2009.03]
Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. [2008.11.11]
The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial. [2008.02]
Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. [2007.10.30]
Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. [2007.09.04]
Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double-blind comparison. [2007.09]
Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. [2007.06]
Comparison of fondaparinux and enoxaparin in acute coronary syndromes. [2006.04.06]
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. [2006.04.05]
Evaluation of wound healing after total knee arthroplasty in a randomized prospective trial comparing fondaparinux with enoxaparin. [2006.03]
Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. [2006.02.11]
Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery. [2006.01]
Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. [2005.12.01]
Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. [2005.10]
Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial. [2005.03.22]
Well-designed clinical trials possibly related to Arixtra (Fondaparinux Subcutaneous)
Diagnosis and treatment of superficial vein thrombosis. [2013]
Is routine chemical thromboprophylaxis after total hip replacement really necessary in a Japanese population? [2011.02]
Anticoagulating obese patients in the modern era. [2011]
A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. [2010.11]
A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. [2010.08.12]
Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes. [2010.01]
A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the
prevention of venous thromboembolism in patients undergoing total knee
arthroplasty. [2010]
Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. [2009.03]
Comparison of a single end point to determine optimal initial warfarin dosing (5 mg versus 10 mg) for venous thromboembolism. [2006.08.15]
Other research related to Arixtra (Fondaparinux Subcutaneous)
Association between the use of fondaparinux vs low-molecular-weight heparin and
clinical outcomes in patients with non-ST-segment elevation myocardial
infarction. [2015]
Prevention of venous thromboembolism in hospitalized acutely ill medical
patients: focus on the clinical utility of (low-dose) fondaparinux. [2013]
[Efficacy and safety of fondaparinux versus enoxaparin for preventing venous
thromboembolism after major orthopedic surgery: a meta-analysis]. [Article in Chinese] [2013]
Bivalirudin versus unfractionated heparin during percutaneous coronary
intervention in patients with non-ST-segment elevation acute coronary syndrome
initially treated with fondaparinux: results from an international, multicenter,
randomized pilot study (SWITCH III). [2013]
Fondaparinux - data on efficacy and safety in special situations. [2011.11.29]
Randomized trial of fondaparinux versus heparin to prevent graft failure after coronary artery bypass grafting: the Fonda CABG study. [2011.10]
[Comparison of platelet monitoring in patients receiving thromboprophylaxis with fondaparinux or a low molecular weight heparin. The Ariane study]. [2011.09]
Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux. [2011.06]
Use of recombinant factor VIIa (NovoSeven((R))) in 8 patients with ongoing life-threatening bleeding treated with fondaparinux. [2011.06]
Use of fondaparinux in a pregnant woman with pulmonary embolism and heparin-induced thrombocytopenia. [2011.05]
Functionality of fondaparinux (pentasaccharide) depends on clinical antithrombin levels. [2011.04]
Prospective study on the efficacies of fondaparinux and enoxaparin in preventing venous thromboembolism after hip fracture surgery. [2011.01]
Randomized trial of fondaparinux versus heparin to prevent graft failure after
coronary artery bypass grafting: the Fonda CABG study. [2011]
Comparison of safety and efficacy between fondaparinux and nadroparin in non-ST
elevation acute coronary syndromes. [2011]
Multidetector-row computed tomography-based clinical assessment of fondaparinux
for treatment of acute pulmonary embolism and acute deep vein thrombosis in
Japanese patients. [2011]
Early postoperative bleeding in polytrauma patients treated with fondaparinux:
literature review and institutional experience. [2011]
Low allergenic potential with fondaparinux: results of a prospective investigation. [2010.10]
Fondaparinux therapy in a hemodialysis patient with heparin-induced thrombocytopenia type II. [2010.07.01]
Fondaparinux (Arixtra(R)), a safe alternative for the treatment of patients with heparin-induced thrombocytopenia? [2010.06]
Update on fondaparinux: role in management of thromboembolic and acute coronary events. [2010.04]
Fondaparinux or enoxaparin: a comparative study of postoperative bleeding in coronary artery bypass grafting surgery. [2010.04]
Routine use of fondaparinux in acute coronary syndromes: a 2-year multicenter experience. [2010.02]
Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis. [2010.02]
Low allergenic potential with fondaparinux: results of a prospective
investigation. [2010]
Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the
Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial. [2010]
Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials. [2009.11.17]
Fondaparinux for prevention of venous thromboembolism in high-risk trauma patients: a pilot study. [2009.11]
Heparin induced thrombocytopenia and re-thrombosis associated with warfarin and fondaparinux in a child. [2009.09]
Fondaparinux: an overview. [2009.06]
Economic and clinical evaluation of fondaparinux vs. enoxaparin for thromboprophylaxis following general surgery. [2009.05]
Heparin-induced thrombocytopenia successfully treated with fondaparinux. [2009.03]
Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6. [2009.03]
[Heparin-induced thrombocythopenia in a patient with massive pulmonary embolism and dilated cardiomyopathy, successfuly treated with fondaparinux - a case report] [2008.12]
Heparin-induced thrombocytopenia--therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes. [2008.12]
Delayed-onset HIT caused by low-molecular-weight heparin manifesting during fondaparinux prophylaxis. [2008.11]
Antithrombotic Therapy With Fondaparinux in Relation to Interventional Management Strategy in Patients With ST- and Non-ST-Segment Elevation Acute Coronary Syndromes. An Individual Patient-Level Combined Analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) Randomized Trials. [2008.10.27]
Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors. [2008.09]
Fondaparinux prevents venous thromboembolism after joint replacement surgery in Japanese patients. [2008.08]
Fondaparinux for the prevention or treatment of venous thromboembolism related to lower limb trauma: evidence today. [2008.04]
Use of fondaparinux as an anticoagulant during hemodialysis: a preliminary study. [2008.04]
[Fondaparinux: the present and the future] [2008.03]
Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. [2008.02]
Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. [2008.01]
Fondaparinux: use in thromboprophylaxis of acute medical patients. [2008]
Fondaparinux sodium: a review of its use in the management of acute coronary syndromes. [2008]
Spotlight on fondaparinux sodium in acute coronary syndromes. [2008]
Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. [2007.12.15]
The safety and efficacy of extended thromboprophylaxis with fondaparinux after major orthopedic surgery of the lower limb with or without a neuraxial or deep peripheral nerve catheter: the EXPERT Study. [2007.12]
Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery. [2007.12]
Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis. [2007.12]
Efficacy and safety of fondaparinux in patients with acute coronary syndromes. [2007.11]
Monitoring fondaparinux with the Sonoclot. [2007.10]
Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography. [2007.09]
Treatment of thrombosis with fondaparinux (Arixtra) in a patient with end-stage renal disease receiving hemodialysis therapy. [2007.08]
The use of graduated compression stockings in association with fondaparinux in surgery of the hip: A MULTICENTRE, MULTINATIONAL, RANDOMISED, OPEN-LABEL, PARALLEL-GROUP COMPARATIVE STUDY. [2007.07]
Minimizing costs for treating deep vein thrombosis: the role for fondaparinux. [2007.06]
Fondaparinux as a treatment option for heparin-induced thrombocytopenia. [2007.06]
Fondaparinux prevents venous thromboembolism after joint replacement surgery in Japanese patients. [2007.04.28]
Fondaparinux: pharmacology and clinical experience in cardiovascular medicine. [2007.04]
Low-dose fondaparinux in suspected heparin-induced thrombocytopenia in the critically ill. [2007.03]
Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery. [2007.01.16]
Management of acute coronary syndromes with fondaparinux. [2007]
Retroperitoneal hematoma due to spontaneous lumbar artery rupture during fondaparinux treatment. Case report and review of the literature. [2007]
|